Prevalence of abnormal cervical cancer screening outcomes among screening-compliant women in the United States

Formal guidelines recommend routine cervical cancer screening using the Papanicolaou test alone, every 3 years, for women aged 21 –65 years; high-risk human papillomavirus testing alone or concurrent hr human papillomavirus and Papanicolaou test (co-testing), every 5 years, for women aged 30–65 years.1–3 Early detection of precursor lesions through routine screening is central to cervical cancer prevention.1 However, lit tle is known about the prevalence of abnormal screening outcomes by cervical cancer screening modality.
Source: American Journal of Obstetrics and Gynecology - Category: OBGYN Authors: Tags: Research Letter Source Type: research